Relevant bibliographies by topics / Plasma biomarker

Academic literature on the topic 'Plasma biomarker'

Author: Grafiati
Published: 9 March 2023
Last updated: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Plasma biomarker.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Plasma biomarker"

1

Balis, Frank M., Cynthia Lester McCully, Christine M. Busch, Elizabeth Fox, and Katherine E. Warren. "Pharmacokinetics of the disialoganglioside, GD2, a circulating tumor biomarker for neuroblastoma, in nonhuman primates." Journal of Circulating Biomarkers 10 (December 3, 2021): 26–29. http://dx.doi.org/10.33393/jcb.2021.2329.

Full text
Abstract:
Background: The ganglioside GD2 is a potential circulating tumor biomarker for the childhood cancer, neuroblastoma. Interpreting the levels of a circulating tumor biomarker depends in part on a knowledge of the biomarker’s clinical pharmacology. Background: The ganglioside GD2 is a potential circulating tumor biomarker for the childhood cancer neuroblastoma. Interpreting the levels of a circulating tumor biomarker depends in part on a knowledge of the biomarker’s clinical pharmacology. Methods: We studied the plasma and cerebrospinal fluid (CSF) pharmacokinetics of the C18 lipoform of GD2 in two nonhuman primates with indwelling subcutaneous CSF lateral ventricular reservoir systems. GD2 was quantified with a validated high-performance liquid chromatography (HPLC)/tandem mass spectrometry assay. GD2 was administered as a short intravenous infusion and frequent plasma and CSF samples were drawn over 72 hours. Results: GD2 plasma concentration declined monoexponentially with a half-life of 16 hours. Clearance was 0.0136 and 0.0131 L/h and volume of distribution (Vd) was 0.035 and 0.038 L/kg in the two animals. Vd was equivalent to plasma volume. Greater than 98% of GD2 in plasma is in a bound form consistent with its known association with lipoproteins and accounting for its limited volume of distribution. GD2 did not cross over from plasma into the CSF. Conclusions: The pharmacokinetic profile of GD2 is favorable for a circulating tumor biomarker. This study demonstrates the value of characterizing the clinical pharmacology of circulating biomarkers to better understand their clinical behavior.
APA, Harvard, Vancouver, ISO, and other styles
2

Mehta, Arpita I., Sally Ross, Mark S. Lowenthal, Vincent Fusaro, David A. Fishman, Emanuel F. Petricoin, and Lance A. Liotta. "Biomarker Amplification by Serum Carrier Protein Binding." Disease Markers 19, no. 1 (2003): 1–10. http://dx.doi.org/10.1155/2003/104879.

Full text
Abstract:
Mass spectroscopic analysis of the low molecular mass (LMM) range of the serum/plasma proteome is a rapidly emerging frontier for biomarker discovery. This study examined the proportion of LMM biomarkers, which are bound to circulating carrier proteins. Mass spectroscopic analysis of human serum following molecular mass fractionation, demonstrated that the majority of LMM biomarkers exist bound to carrier proteins. Moreover, the pattern of LMM biomarkers bound specifically to albumin is distinct from those bound to non-albumin carriers. Prominent SELDI-TOF ionic species (m/z 6631.7043) identified to correlate with the presence of ovarian cancer were amplified by albumin capture. Several insights emerged: a) Accumulation of LMM biomarkers on circulating carrier proteins greatly amplifies the total serum/plasma concentration of the measurable biomarker, b) The total serum/plasma biomarker concentration is largely determined by the carrier protein clearance rate, not the unbound biomarker clearance rate itself, and c) Examination of the LMM species bound to a specific carrier protein may contain important diagnostic information. These findings shift the focus of biomarker detection to the carrier protein and its biomarker content.
APA, Harvard, Vancouver, ISO, and other styles
3

Lim, Yen Ying, Paul Maruff, Naoki Kaneko, James Doecke, Christopher Fowler, Victor L. Villemagne, Takashi Kato, et al. "Plasma Amyloid-β Biomarker Associated with Cognitive Decline in Preclinical Alzheimer’s Disease." Journal of Alzheimer's Disease 77, no. 3 (September 29, 2020): 1057–65. http://dx.doi.org/10.3233/jad-200475.

Full text
Abstract:
Background: Using immunoprecipitation-mass spectrometry, we recently developed and validated a plasma composite biomarker for the assessment of amyloid-β (Aβ) levels. However, as yet, its relationship with clinical outcomes remains unclear. Objective: We aimed to examine the relationship between this plasma Aβ composite biomarker and cognitive function in cognitively normal older adults in two independent cohorts. Methods: Participants enrolled in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study and the National Centre for Geriatrics and Gerontology (NCGG) study had undergone Aβ neuroimaging using positron emission tomography (PET), cognitive assessments and provided blood samples. We derived a high-performance plasma Aβ composite biomarker by immunoprecipitation with mass-spectrometry. Results: Both continuous and categorical measures of the plasma Aβ composite biomarker were significantly related to decline in episodic memory and executive function. The magnitude of effects of the plasma Aβ composite on episodic memory and executive function were comparable to that observed for the effects of PET Aβ levels on these same outcome measures. Conclusion: Several plasma Aβ biomarkers have been developed, but none have yet been applied to investigate their relationship with cognitive outcomes. Our results have important implications for the use of this biomarker in the detection of at-risk individuals.
APA, Harvard, Vancouver, ISO, and other styles
4

Meng, Ran, and Xunming Ji. "Plasma Biomarker and Stroke." Cerebrovascular Diseases 32, no. 4 (2011): 406. http://dx.doi.org/10.1159/000331927.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Yang, Chun-Ju, Hai Yan, Naimei Tang, Yi Zou, Yas Al-Hadeethi, Xiaochuan Xu, Hamed Dalir, and Ray T. Chen. "Ultra Sensitivity Silicon-Based Photonic Crystal Microcavity Biosensors for Plasma Protein Detection in Patients with Pancreatic Cancer." Micromachines 11, no. 3 (March 9, 2020): 282. http://dx.doi.org/10.3390/mi11030282.

Full text
Abstract:
Defect-engineered photonic crystal (PC) microcavities were fabricated by UV photolithography and their corresponding sensitivities to biomarkers in patient plasma samples were compared for different resonant microcavity characteristics of quality factor Q and biomarker fill fraction. Three different biomarkers in plasma from pancreatic cancer patients were experimentally detected by conventional L13 defect-engineered microcavities without nanoholes and higher sensitivity L13 PC microcavities with nanoholes. 8.8 femto-molar (0.334 pg/mL) concentration of pancreatic cancer biomarker in patient plasma samples was experimentally detected which are 50 times dilution than ELISA in a PC microcavity with high quality factor and high analyte fill fraction.
APA, Harvard, Vancouver, ISO, and other styles
6

Vrba, Lukas, and Bernard W. Futscher. "DNA methylation changes in biomarker loci occur early in cancer progression." F1000Research 8 (December 16, 2019): 2106. http://dx.doi.org/10.12688/f1000research.21584.1.

Full text
Abstract:
Tumor-specific DNA methylation can be used for cancer diagnostics and monitoring. We have recently reported a set of DNA methylation biomarkers that can distinguish plasma samples from lung cancer patients versus healthy controls with high sensitivity and specificity. Furthermore, the DNA methylation signal from the biomarker loci detected in plasma samples correlated with tumor size and decreased after surgical resection of lung tumors. In order to determine the timing of DNA methylation of these loci during carcinogenesis and thus the potential of the biomarkers to detect early stages of the disease we analyzed the DNA methylation of the biomarker loci in five precancerous conditions using available data from the GEO database. We found that the DNA methylation of the biomarker loci is gained early in carcinogenesis since most of the precancerous conditions already have biomarker loci hypermethylated. Moreover, these DNA methylation biomarkers are able to distinguish between precancerous lesions with malignant potential and those that stay benign where data is available. Taken together, the biomarkers have the potential to detect the earliest cancer stages; the only limitation to detection of cancer from plasma samples or other liquid biopsies is the timing when tumors start to shed enough DNA into body fluids.
APA, Harvard, Vancouver, ISO, and other styles
7

Vrba, Lukas, and Bernard W. Futscher. "DNA methylation changes in biomarker loci occur early in cancer progression." F1000Research 8 (February 14, 2020): 2106. http://dx.doi.org/10.12688/f1000research.21584.2.

Full text
Abstract:
Tumor-specific DNA methylation can be used for cancer diagnostics and monitoring. We have recently reported a set of DNA methylation biomarkers that can distinguish plasma samples from lung cancer patients versus healthy controls with high sensitivity and specificity. Furthermore, the DNA methylation signal from the biomarker loci detected in plasma samples correlated with tumor size and decreased after surgical resection of lung tumors. In order to determine the timing of DNA methylation of these loci during carcinogenesis and thus the potential of the biomarkers to detect early stages of the disease we analyzed the DNA methylation of the biomarker loci in five precancerous conditions using available data from the GEO database. We found that the DNA methylation of the biomarker loci is gained early in carcinogenesis since most of the precancerous conditions already have biomarker loci hypermethylated. Moreover, these DNA methylation biomarkers are able to distinguish between precancerous lesions with malignant potential and those that stay benign where data is available. Taken together, the biomarkers have the potential to detect the earliest cancer stages; the only limitation to detection of cancer from plasma samples or other liquid biopsies is the timing when tumors start to shed enough DNA into body fluids.
APA, Harvard, Vancouver, ISO, and other styles
8

Ebadi, Maryam, and Vera C. Mazurak. "Potential Biomarkers of Fat Loss as a Feature of Cancer Cachexia." Mediators of Inflammation 2015 (2015): 1–8. http://dx.doi.org/10.1155/2015/820934.

Full text
Abstract:
Fat loss is associated with shorter survival and reduced quality of life in cancer patients. Effective intervention for fat loss in cachexia requires identification of the condition using prognostic biomarkers for early detection and prevention of further depletion. No biomarkers of fat mass alterations have been defined for application to the neoplastic state. Several inflammatory cytokines have been implicated in mediating fat loss associated with cachexia; however, plasma levels may not relate to adipose atrophy. Zinc-α2-glycoprotein may be a local catabolic mediator within adipose tissue rather than serving as a plasma biomarker of fat loss. Plasma glycerol and leptin associate with adipose tissue atrophy and mass, respectively; however, no study has evaluated their potential as a prognostic biomarker of cachexia-associated fat loss. This review confirms the need for further studies to identify valid prognostic biomarkers to identify loss of fat based on changes in plasma levels of biomarkers.
APA, Harvard, Vancouver, ISO, and other styles
9

Dan, Kisoon, Ji Eun Lee, Dohyun Han, Sun Min Kim, Subeen Hong, Hyeon Ji Kim, and Kyo Hoon Park. "Proteomic identification of biomarkers in maternal plasma that predict the outcome of rescue cerclage for cervical insufficiency." PLOS ONE 16, no. 4 (April 15, 2021): e0250031. http://dx.doi.org/10.1371/journal.pone.0250031.

Full text
Abstract:
Objective We sought to identify plasma protein biomarkers that are predictive of the outcome of rescue cerclage in patients with cervical insufficiency. Methods This retrospective cohort study included 39 singleton pregnant women undergoing rescue cerclage for cervical insufficiency (17–25 weeks) who gave plasma samples. Three sets of pooled plasma samples from controls (cerclage success, n = 10) and cases (cerclage failure, n = 10, defined as spontaneous preterm delivery at <33 weeks) were labeled with 6-plex tandem mass tag (TMT) reagents and analyzed by liquid chromatography-tandem mass spectrometry. Differentially expressed proteins between the two groups were selected from the TMT-based quantitative analysis. Multiple reaction monitoring-mass spectrometry (MRM-MS) analysis was further used to verify the candidate proteins of interest in patients with cervical insufficiency in the final cohort (n = 39). Results From MRM-MS analysis of the 40 proteins showing statistically significant changes (P < 0.05) from the TMT-based quantitative analysis, plasma IGFBP-2, PSG4, and PGLYRP2 levels were found to be significantly increased, whereas plasma MET and LXN levels were significantly decreased in women with cerclage failure. Of these, IGFBP-2, PSG4, and LXN levels in plasma were independent of cervical dilatation. A multiple-biomarker panel was developed for the prediction of cerclage failure, using a stepwise regression procedure, which included the plasma IGFBP-2, PSG4, and LXN (area under the curve [AUC] = 0.916). The AUC for this multiple-biomarker panel was significantly greater than the AUC for any single biomarker included in the multi-biomarker model. Conclusions Proteomic analysis identified useful and independent plasma biomarkers (IGFBP-2, PSG4, and LXN; verified by MRM) that predict poor pregnancy outcome following rescue cerclage. Their combined analysis in a multi-biomarker panel significantly improved predictability.
APA, Harvard, Vancouver, ISO, and other styles
10

Collard, Harold R., Carolyn S. Calfee, Paul J. Wolters, Jin Woo Song, Sang-Bum Hong, Sandra Brady, Akitoshi Ishizaka, et al. "Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis." American Journal of Physiology-Lung Cellular and Molecular Physiology 299, no. 1 (July 2010): L3—L7. http://dx.doi.org/10.1152/ajplung.90637.2008.

Full text
Abstract:
Little is known about the pathobiology of acute exacerbation of idiopathic pulmonary fibrosis (IPF), a condition that shares clinical and histopathological features with acute lung injury. Plasma biomarkers have been well studied in acute lung injury and have provided insight into the underlying disease mechanism. The objective of this study was to determine the plasma biomarker profile of acute exacerbation of IPF and compare this profile with that of stable IPF and acute lung injury. Plasma was collected from patients with stable IPF, acute exacerbation of IPF, and acute lung injury for measurement of biomarkers of cellular activity/injury (receptor for advanced glycation endproducts, surfactant protein D, KL-6, von Willebrand factor), systemic inflammation (IL-6), and coagulation/fibrinolysis (protein C, thrombomodulin, plasminogen activator inhibitor-1). Plasma from patients with acute exacerbation of IPF showed significant elevations in markers of type II alveolar epithelial cell injury and/or proliferation, endothelial cell injury, and coagulation. This profile differed from the biomarker profile in patients with acute lung injury. These findings support the hypothesis that type II alveolar epithelial cells are centrally involved in the pathobiology of acute exacerbation of IPF. Furthermore, they suggest that acute exacerbation of IPF has a distinct plasma biomarker profile from that of acute lung injury.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Plasma biomarker"

1

Fisher, Christal. "Quantitative analysis of the plasma proteome in pre-eclampsia." Thesis, University of Manchester, 2012. https://www.research.manchester.ac.uk/portal/en/theses/quantitative-analysis-of-the-plasma-proteome-in-preeclampsia(3e207341-ebb9-4cb0-b7ea-34b9b110eda6).html.

Full text
Abstract:
There is currently no clinically useful screening test available to identify nulliparous women at high risk of developing pre-eclampsia. This study aimed to identify novel biomarkers using hypothesis generating proteomic methods applied to plasma samples obtained prior to clinical diagnosis of pre-eclampsia. Plasma samples taken at 15 weeks gestation from women who subsequently developed late pre-eclampsia (> 34 weeks), early pre-eclampsia (< 34 weeks) and two distinct groups of women with uncomplicated pregnancies (each n=12) were pooled. Pooled plasma was immunodepleted, labelled using iTRAQ-8 plex reagent and separated into fractions using high pH reverse phase chromatography. Fractions were analysed by LC-MS/MS and data interrogated using ProteinPilot 3.0. The merits of two immunodepletion systems were compared; the Seppro® IgY 14 -SuperMix LC column system removes up to 100 highly abundant plasma proteins and the Multiple Affinity Removal LC column depletes 14 highly abundant plasma proteins. Removal of more high abundance proteins allowed identification of more, potentially interesting, low abundance proteins, but was less reproducible than removing fewer proteins. Two methods of LC-MS/MS analysis were assessed; the QStar XL qTOF and 5800 MALDI-TOF-TOF. The protein identifications and the quantification data acquired by each method was comparable and complementary and increased the total number of proteins identified. A total of 502 proteins were identified. A stringent two stage analysis was developed to identify candidate proteins which changed in abundance in plasma from women who later developed pre-eclampsia compared to women with uncomplicated pregnancies. Analysis identified a total of 113 proteins which were both reproducibly quantified and changed by more than the expected range of biological variation. Six candidate proteins changed in abundance in the plasma taken from women who subsequently developed early pre-eclampsia were selected for further validation. A high throughput, low cost, method of multiple reaction monitoring which allows relative quantitation without the use of costly isotopically labelled peptides was developed to validate candidate proteins. Candidate proteins were also assessed by western blot and ELISA. Only one candidate protein; platelet basic protein, was validated by all three methods and demonstrated similar increases in the abundance. This investigation suggests that measurement of platelet basic protein at 15 weeks gestation is a novel candidate predictive marker for pre-eclampsia. Validation of platelet basic protein in a large, independent, sample set is required to confirm changes in protein expression and to evaluate potential, alongside other factors, to identify nulliparous women at high risk of developing pre-eclampsia later in pregnancy.
APA, Harvard, Vancouver, ISO, and other styles
2

Mohsenchian, Atefeh. "Biomarker discovery for ALS by using affinity proteomica." Thesis, KTH, Skolan för bioteknologi (BIO), 2012. http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-149440.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ghobadi, Bita. "Suggestions for optimal biomarker miRNA extraction from plasma of sepsis patients." Thesis, Högskolan i Skövde, Institutionen för biovetenskap, 2020. http://urn.kb.se/resolve?urn=urn:nbn:se:his:diva-18935.

Full text
Abstract:
Sepsis is a life-threatening organ disfunction, which is caused by a dysfunctional immuneresponse and develops when an infection overwhelms the body’s defense mechanism and causesand uncontrolled inflammatory response. Biomarkers have a great impact on helping diagnosisand treatments of sepsis. The biomarkers, like miRNA, are needed for both more accurate andquicker diagnosis of sepsis in patients. The future diagnostics are looking at other types ofbiomarkers, e.g. miRNA, but low amounts of miRNA are present in biofluids and make itchallenging to quantify. A new methodology is needed which is both accurate and does notrequire a lot of fluid. The aim of this project was to identify which kit of two kits and which oftwo volumes of plasma would lead to the highest concentration of miRNA and highest quality ofmiRNA extracted. This was quantified by using two different volumes, 100 μl and 200 μl, andextracting the two volumes with both exoRNeasy Serum/Plasma midi kit (Qiagen) and TotalRNA Purification kit (Norgen). There was no statistical difference between median miRNAconcentrations between the two volumes within the Qiagen kit. However, the mean miRNAconcentration (0.833 ng/μl) obtained from the Norgen kit (100 μl plasma starting volume) wasstatistically higher than the mean miRNA concentration (0.570 ng/μl) obtained from the samekit with 200 μl, p = 0.033. The optimal kit and volume of this study is the Norgen kit with 100 μl.Further studies are needed to verify these results.
APA, Harvard, Vancouver, ISO, and other styles
4

Papadia, Cinzia. "Plasma citrulline concentration : A biomarker of entercyte absorptive capacity in intestinal failure." Thesis, Imperial College London, 2010. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.516555.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Van, der Vaart Maniesh. "Characterization of circulating DNA as a biomarker for genetic aberrations in humans / Maniesh van der Vaart." Thesis, North-West University, 2006. http://hdl.handle.net/10394/1329.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

NI, JIAQIAN. "Plasma Biomarkers for Age-Related Macular Degeneration." Cleveland State University / OhioLINK, 2009. http://rave.ohiolink.edu/etdc/view?acc_num=csu1236700270.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Caranci, Giovanni. "Plasma alpha synuclein assay in Parkinson's disease and parkinsonisms." Doctoral thesis, Università di Catania, 2013. http://hdl.handle.net/10761/1322.

Full text
Abstract:
In this observational cross-sectional study, using an immunoenzymatic technique we assayed and compared total plasma alpha-synuclein concentrations in 69 patients with Parkinson's disease and 110 age-matched healthy control subjects. Two previously unreported findings concerned gender. First, plasma alpha-synuclein concentrations measured in the more advanced parkinsonian disease stages decreased in men but not in women. Second, again only in men, plasma alphasynuclein concentration was associated with cognitive impairments, hallucinations, depressed mood and sleep disorders. These findings underline the gender-related differences in parkinsonian patients and indicate plasma alpha-synuclein expression as a potential biological marker for Parkinson's disease progression in men.
APA, Harvard, Vancouver, ISO, and other styles
8

Xu, Haili, Timothy Radabaugh, Zhenqiang Lu, Michael Galligan, Dean Billheimer, Donata Vercelli, Anne L. Wright, Terrence J. Monks, Marilyn Halonen, and Serrine S. Lau. "Exploration of early-life candidate biomarkers for childhood asthma using antibody arrays." WILEY-BLACKWELL, 2016. http://hdl.handle.net/10150/621762.

Full text
Abstract:
Background: Proteomic approaches identifying biomarkers have been applied to asthma to only a very limited extent. Methods: With an antibody array (RayBiotech, Norcross, GA, USA), the relative intensity and rank differences of 444 proteins were compared in 24 plasma samples obtained at age 3, 11 from children with and 12 without asthma diagnoses at ages 5 and 9. Protein candidates identified by antibody array were quantitated by ELISA in an enlarged sample. Proteins found to differentiate children with and without asthma were also examined for association with known Year 1 asthma risk factors, eczema, and wheeze. Results: In the antibody array, four proteins had rank differences between asthma and non-asthma groups (FDR < 0.1). By ELISA, mean log (+/- s.e.m.) erythropoietin (EPO) level (IU/l) was lower (0.750 +/- 0.048 vs. 0.898 +/- 0.035; p = 0.006) and mean (+/- s.e.m.) soluble GP130 (sGP130) level (ng/ml) was higher in the asthma vs. the non-asthma group (302 +/- 13 vs. 270 +/- 8; p = 0.041). The other 2 array proteins (galactin-3 and eotaxin-3) did not differ by ELISA by asthma. EPO related to the asthma risk factor, first year eczema, whereas sGP130 related to first year wheeze. Conclusions: Through two independent assessments, age 3 plasma levels of EPO and sGP130 were found related to childhood asthma.
APA, Harvard, Vancouver, ISO, and other styles
9

Oda, Hiroki. "Plasma microRNAs Are Potential Biomarkers of Acute Rejection After Hindlimb Transplantation in Rats." Kyoto University, 2018. http://hdl.handle.net/2433/232087.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Tegg, Michelle. "Plasma insulin-degrading enzyme: Characterisation and evaluation as a potential biomarker for Alzheimer's disease." Thesis, Edith Cowan University, Research Online, Perth, Western Australia, 2014. https://ro.ecu.edu.au/theses/1198.

Full text
Abstract:
Alzheimer’s disease (AD) is increasing in prevalence due to increasing lifespan and altered lifestyle. It is the fourth major cause of death in Western countries, resulting in significant economic and social impact (Von Strauss, et al., 1999; Goate, 1997). There are no blood biomarkers currently accepted for the diagnosis of AD, and the identification of suitable biomarkers would eventually reduce the necessity for invasive, expensive and slow diagnostic procedures, as well as facilitate prognostic studies. An AD blood test would decrease the need for delaying diagnosis due to ambivalent presentation, and allow therapeutic intervention to commence at an earlier and more functional stage for the sufferer, thereby maximising the benefits of treatment. It is also feasible that a blood biomarker would be of use in the development of therapeutic treatments, which are currently inadequate. Numerous studies have suggested that hyperinsulinemia and type II diabetes (DM2) significantly increase the risk of developing Alzheimer’s disease (AD). Therefore, much research interest has been aimed recently toward determining the putative common mechanisms of these conditions. One enzyme which has been implicated in both AD and DM2 is insulin degrading enzyme (IDE). This project focuses largely on the characterisation of plasma IDE expression and catalytic activity, to help determine potential role/s of IDE in the development of AD, and the suitability of IDE as an AD biomarker. Evidence is also provided to support the concept that IDE impairments may be the common factor that links AD, hyperinsulinemia and DM2.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Plasma biomarker"

1

Biogenic monoamines and their metabolites in the urine, plasma, and cerebrospinal fluid of normal, psychiatric, and neurological subjects. Boca Raton, Fla: CRC Press, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Brouwers, Martijn C. G. J. Approach to the Patient with General Symptoms. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199972135.003.0073.

Full text
Abstract:
Fatigue and fever of unknown origin are frequently encountered symptoms at the general internal medicine outpatient clinic. Careful history taking and physical examination are essential in the detection of an inherited metabolic disease, since biomarkers, such as plasma lactate and creatine kinase levels, have low positive predictive values. Absence of any specific symptom or sign of an inherited metabolic disease do not advocate additional investigations.
APA, Harvard, Vancouver, ISO, and other styles
3

Virological Safety Aspects of Plasma Derivatives: Cannes (Developments in Biologicals). S. Karger AG (Switzerland), 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Virological safety aspects of plasma derivative: Cannes (France) November 3-6, 1992. Basel: Karger, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Mochel, Fanny. Spastic Paraplegia Type 5. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199972135.003.0041.

Full text
Abstract:
Spastic paraplegia type 5 (SPG5) is an autosomal recessive hereditary spastic paraplegia due to mutations in CYP7B1, which encodes oxysterol 7α‎-hydroxylase. Oxysterol 7α‎-hydroxylase is involved in the synthesis of bile acids from cholesterol. CYP7B1 mutations are responsible for rare forms of liver failure in infancy as well as lower motor neuron degeneration in adults with no obvious genotype-phenotype correlation. SPG5 is mostly characterized by spastic paraplegia with prominent posterior column sensory impairment that can lead to sensory ataxia and bladder dysfunction. SPG5 can easily be diagnosed thanks to the significant elevation of two plasma oxysterols: 27- and 25-hydroxycholesterol. Accordingly, plasma oxysterols are biomarkers that should be included in the screening of any spastic paraplegia of unknown etiology. Furthermore, the dramatic therapeutic response of a child with liver failure due to CYP7B1 mutations using chenodeoxycholic acid opens promising therapeutic perspectives for SPG5 patients, possibly as in cerebrotendinous xanthomatosis.
APA, Harvard, Vancouver, ISO, and other styles
6

McKeon, Andrew. Autoimmune Encephalitis. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199937837.003.0097.

Full text
Abstract:
Autoimmune encephalitis clinically encapsulates a spectrum of disorders including limbic encephalitis, and other autoimmune CNS disorders, which often have a paraneoplastic cause. Unlike multiple sclerosis, autoimmune encephalitides are unified by well-characterized neural-specific IgG biomarkers detectable in serum or CSF. Diagnostic laboratory, in vitro and neuropathological studies have demonstrated two broad groups. The first, characterizable by the detection of neuronal nuclear, cytoplasmic, or nucleolar antibodies (such as ANNA-1, aka anti-Hu), likely have a cytotoxic T cell mediated pathogenesis. The second, characterizable by the detection of antibodies targeting plasma membrane antigens, such as NMDA receptor, are likely mediated (at least in part) by pathogenic antibody.
APA, Harvard, Vancouver, ISO, and other styles
7

Gahan, Peter, and Asif Butt. Circulating Nucleic Acids in Plasma and Serum IV (Annals of the New York Academy of Sciences). Blackwell Publishing Limited, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Y. M. Dennis Lo (Editor), Rossa W. K. Chiu (Editor), and Philip J. Johnson (Editor), eds. Circulating Nucleic Acids in Plasma or Serum II (Annals of the New York Academy of Sciences, V. 945). New York Academy of Sciences, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

(Editor), Philippe Anker, and Maurice Strown (Editor), eds. Circulating Nucleic Acids in Plasma or Serum (Annals of the New York Academy of Sciences, V. 906). New York Academy of Sciences, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Wells, Elizabeth M. Anti-N-Methyl-D-Aspartate Receptor Encephalitis. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199937837.003.0091.

Full text
Abstract:
Anti- N-methyl-D-aspartate receptor (NMDAR) encephalitis is a severe but treatable recently identified form of immune-mediated encephalitis associated with antibodies in serum and cerebrospinal fluid (CSF) against the GluN1 subunit of the NMDAR. Research has rapidly expanded the understanding of disease mechanisms and how the condition manifests in different populations (e.g., pediatrics vs. adult, cancer vs. noncancer, male vs. female). Immunocytochemical, physiological, and molecular studies of the effects of human CSF on the rodent and murine brain in vitro and in vivo indicate a noncytotoxic antibody-mediated mechanism of disease pathogenesis. Finding positive antibodies prompts a search for occult neoplasm, most likely ovarian teratoma in young women; other age groups and male patients are less likely to have tumor but need to be screened. Fifty percent of patients respond to first line steroids, IVIG, plasma exchange or a combination, and many others improve with addition of rituximab or cyclophosphamide. Cured patients may have cognitive or motor sequelae, and refractory disease and death may occur despite treatment. Knowledge about etiology and biomarkers of refractory disease are lacking. Additional work is needed to further elucidate the origin of the immune-mediated response, to determine optimal clinical management and develop effective therapies for refractory patients.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Plasma biomarker"

1

Garcia, Sheila, Paulo A. Baldasso, Paul C. Guest, and Daniel Martins-de-Souza. "Depletion of Highly Abundant Proteins of the Human Blood Plasma: Applications in Proteomics Studies of Psychiatric Disorders." In Multiplex Biomarker Techniques, 195–204. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-6730-8_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Léonard, Jean-Francois, Martine Courcol, and Jean-Charles Gautier. "Optimization of SELDI for Biomarker Detection in Plasma." In Methods in Molecular Biology, 351–68. Totowa, NJ: Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-849-2_22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Taleb, Raghda Saad Zaghloul, Pacint Moez, Doreen Younan, Martin Eisenacher, Matthias Tenbusch, Barbara Sitek, and Thilo Bracht. "Protein Biomarker Discovery Using Human Blood Plasma Microparticles." In Methods in Molecular Biology, 51–64. New York, NY: Springer New York, 2019. http://dx.doi.org/10.1007/978-1-4939-9164-8_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Harel, Michal, and Tamar Geiger. "Plasma Biomarker Identification and Quantification by Microparticle Proteomics." In Methods in Molecular Biology, 477–86. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-7057-5_33.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Jia, Lulu. "Comparing Plasma and Urinary Proteomes to Understand Kidney Function." In Urine Proteomics in Kidney Disease Biomarker Discovery, 187–93. Dordrecht: Springer Netherlands, 2014. http://dx.doi.org/10.1007/978-94-017-9523-4_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Bittar, Luis F., Erich V. De Paula, Aline Barnabé, Bruna M. Mazetto, Kiara C. S. Zapponi, Silmara A. L. Montalvão, Marina P. Colella, Fernanda A. Orsi, and Joyce M. Annichino-Bizzacchi. "Plasma Factor VIII Levels as a Biomarker for Venous Thromboembolism." In Biomarkers in Cardiovascular Disease, 703–21. Dordrecht: Springer Netherlands, 2016. http://dx.doi.org/10.1007/978-94-007-7678-4_22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Bittar, Luis F., Erich V. De Paula, Aline Barnabé, Bruna M. Mazetto, Kiara C. S. Zapponi, Silmara A. L. Montalvão, Marina P. Colella, Fernanda A. Orsi, and Joyce M. Annichino-Bizzacchi. "Plasma Factor VIII Levels as a Biomarker for Venous Thromboembolism." In Biomarkers in Cardiovascular Disease, 1–19. Dordrecht: Springer Netherlands, 2015. http://dx.doi.org/10.1007/978-94-007-7741-5_22-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Jarrold, Brad, Alex Varbanov, and Feng Wang. "The Use of Two-Dimensional Gel Electrophoresis for Plasma Biomarker Discovery." In Biomarker Methods in Drug Discovery and Development, 171–87. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-463-6_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

de Faria, Ana Paula, Rodrigo Modolo, and Heitor Moreno. "Plasma 8-Isoprostane as a Biomarker and Applications to Cardiovascular Disease." In Biomarkers in Cardiovascular Disease, 467–88. Dordrecht: Springer Netherlands, 2016. http://dx.doi.org/10.1007/978-94-007-7678-4_31.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

de Faria, Ana Paula, Rodrigo Modolo, and Heitor Moreno. "Plasma 8-Isoprostane as a Biomarker and Applications to Cardiovascular Disease." In Biomarkers in Cardiovascular Disease, 1–22. Dordrecht: Springer Netherlands, 2015. http://dx.doi.org/10.1007/978-94-007-7741-5_31-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Plasma biomarker"

1

Mo, Jue, Sana Siddiqui, Stuart Maudsley, Huey Cheung, Bronwen Martin, and Calvin A. Johnson. "Classification of Alzheimer Diagnosis from ADNI Plasma Biomarker Data." In BCB'13: ACM-BCB2013. New York, NY, USA: ACM, 2013. http://dx.doi.org/10.1145/2506583.2506637.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Chi, Su Young, Hong Joon Shin, Hee Jung Ban, Byeong Kab Yoon, In Jae Oh, Yong Soo Kwon, Kyu Sik Kyu-Sik, et al. "Effectiveness Of Plasma ProGRP As A Biomarker For Lung Cancer." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a3493.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Syed, Maaz, Zaid Iskander, Alexander Fletcher, Samuel Debono, Marc Dweck, Jeffrey T. J. Huang, Calvin Chin, David Newby, and Anna Maria Choy. "BS7 Plasma desmosine as a biomarker in acute aortic syndrome." In British Cardiovascular Society Virtual Annual Conference, ‘Cardiology and the Environment’, 7–10 June 2021. BMJ Publishing Group Ltd and British Cardiovascular Society, 2021. http://dx.doi.org/10.1136/heartjnl-2021-bcs.205.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Azevedo, Fernanda Reis de, Michael Polydefkis, Simina Ticau, David Erbe, Anastasia McManus, Emre Aldinc, David Adams, Mary Reilly, Akshay Vaishnaw, and Paul Nio. "Neurofilament Light Chain (NfL) as a Potential Biomarker of Treatment Response in Hereditary TransthyretinMediated (hATTR) Amyloidosis: Patisiran Global OLE Study." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.200.

Full text
Abstract:
Introduction: Patisiran is approved for the treatment of hATTR amyloidosis with polyneuropathy and its long-term efficacy/safety is being studied in a Global OLE. Plasma biomarkers are being investigated for utility in facilitating earlier diagnosis and monitoring disease /treatment response. Objective: Evaluate long-term change in neurofilament light chain (NfL) levels in response to patisiran in patients enrolled in the Global Open-Label Extension (OLE) study. Methods: NfL plasma levels were measured in duplicate in healthy controls and patients with ATTRv amyloidosis with polyneuropathy using the Quanterix Simoa platform. Patient samples were analyzed from the APOLLO study at baseline and 18 months, and also measured at 12 and 24 months following APOLLO in patients who rolled into the Global OLE. Results: NfL levels at APOLLO baseline were 63.2 (placebo) and 72.1 pg/ mL (patisiran). NfL increased during APOLLO in the placebo group (99.5 pg/mL), whereas a significant decrease was observed at 18 months following patisiran (48.8 pg/mL). Reduced NfL levels were maintained in the APOLLO-patisiran group through 24 months of additional patisiran treatment in the Global OLE (44.0 pg/mL), consistent with maintained improvement in mNIS+7. Upon initiation of patisiran in the Global OLE, the APOLLO-placebo group experienced a reduction in NfL levels through 24 months (44.2 pg/mL), reaching a similar level to the APOLLO-patisiran group. Conclusions: NfL may serve as a biomarker of active nerve damage and polyneuropathy, making it useful as a potential biomarker of disease progression, treatment response and for earlier diagnosis of polyneuropathy in patients with ATTRv amyloidosis and monitoring disease.
APA, Harvard, Vancouver, ISO, and other styles
5

Rajasekar, P., S. M. Thompson, J. Patel, I. Adejumo, J. MacIsaac, D. T. S. Lin, A. J. Knox, et al. "Differential Methylation of Plasma Cell Free DNA: A Potential Asthma Biomarker?" In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a2371.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Isshiki, T., H. Shimizu, A. Yamasaki, S. Miyoshi, Y. Nakamura, S. Sakamoto, S. A. Homma, and K. Kishi. "Plasma Autotaxin Is a Novel Biomarker for Chronic Fibrosing Interstitial Pneumonia." In American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a4232.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mathai, Susan K., Andrew M. Tager, and Barry S. Shea. "Plasma Autotaxin Activity Is A Potential Biomarker For Idiopathic Pulmonary Fibrosis." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a4941.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Fabelo, Himar, Raquel Leon, Samuel Ortega, Francisco Balea-Fernandez, Cristina Bilbao, Gustavo M. Callico, and Ana Wagner. "Novel Methodology for Alzheimer's Disease Biomarker Identification in Plasma using Hyperspectral Microscopy." In 2020 XXXV Conference on Design of Circuits and Integrated Systems (DCIS). IEEE, 2020. http://dx.doi.org/10.1109/dcis51330.2020.9268654.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Chen, Kexin. "Abstract 4135: Plasma miRNAs as potential predictive/prognostic biomarker for ovarian cancer." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-4135.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Plinta, Klaudia, Krzysztof Pawlicki, Michał Morek, Edyta Bogunia, Andrzej Plewka, and Monika Rudzińska-Bar. "D11 Plasma brain-derived neurotrophic factor level as huntington disease severity biomarker." In EHDN 2018 Plenary Meeting, Vienna, Austria, Programme and Abstracts. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/jnnp-2018-ehdn.93.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Plasma biomarker"

1

Harris, Kevin W. Breast Cancer Microvesicles as a Novel Plasma Biomarker and Therapeutic Target (IDEA). Fort Belvoir, VA: Defense Technical Information Center, April 2008. http://dx.doi.org/10.21236/ada487982.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Harris, Kevin W. Breast Cancer Microvesicles as a Novel Plasma Biomarker and Therapeutic Target (IDEA). Fort Belvoir, VA: Defense Technical Information Center, April 2009. http://dx.doi.org/10.21236/ada513009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Harris, Kevin. Breast Cancer Microvesicles as a Novel Plasma Biomarker and Therapeutic Target (IDEA). Fort Belvoir, VA: Defense Technical Information Center, April 2010. http://dx.doi.org/10.21236/ada548619.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Harris, Kevin W. Breast Cancer Microvesicles as a Novel Plasma Biomarker and Therapeutic Target (IDEA). Fort Belvoir, VA: Defense Technical Information Center, April 2007. http://dx.doi.org/10.21236/ada470575.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Janech, Michael G. Identification and Validation of Plasma Biomarkers in California Sea Lions. Fort Belvoir, VA: Defense Technical Information Center, April 2014. http://dx.doi.org/10.21236/ada602905.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Vogelzang, Nicolas, and Louis Fink. Longitudinal Bank for Serum, Plasma, and DNA for Detection of Biomarkers. Office of Scientific and Technical Information (OSTI), November 2007. http://dx.doi.org/10.2172/919465.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ward, David C. Longitudinal Bank for Serum, Plasma and DNA for Detection of Biomarkers. Office of Scientific and Technical Information (OSTI), January 2009. http://dx.doi.org/10.2172/959424.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Plasma biomarker' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography